DK316988A - Transdermalt farmaceutisk praeparat og dets anvendelse - Google Patents

Transdermalt farmaceutisk praeparat og dets anvendelse

Info

Publication number
DK316988A
DK316988A DK316988A DK316988A DK316988A DK 316988 A DK316988 A DK 316988A DK 316988 A DK316988 A DK 316988A DK 316988 A DK316988 A DK 316988A DK 316988 A DK316988 A DK 316988A
Authority
DK
Denmark
Prior art keywords
pharmaceutical preparation
transdermal pharmaceutical
transdermal
preparation
pharmaceutical
Prior art date
Application number
DK316988A
Other languages
Danish (da)
English (en)
Other versions
DK316988D0 (da
Inventor
John Michael Pawelchak
James Ronald Lawter
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of DK316988D0 publication Critical patent/DK316988D0/da
Publication of DK316988A publication Critical patent/DK316988A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
DK316988A 1987-06-12 1988-06-10 Transdermalt farmaceutisk praeparat og dets anvendelse DK316988A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/061,934 US5001139A (en) 1987-06-12 1987-06-12 Enchancers for the transdermal flux of nivadipine

Publications (2)

Publication Number Publication Date
DK316988D0 DK316988D0 (da) 1988-06-10
DK316988A true DK316988A (da) 1988-12-13

Family

ID=22039100

Family Applications (1)

Application Number Title Priority Date Filing Date
DK316988A DK316988A (da) 1987-06-12 1988-06-10 Transdermalt farmaceutisk praeparat og dets anvendelse

Country Status (13)

Country Link
US (1) US5001139A (no)
EP (1) EP0321636A3 (no)
JP (1) JPS6413023A (no)
KR (1) KR890000091A (no)
AU (1) AU614523B2 (no)
CA (1) CA1305419C (no)
DK (1) DK316988A (no)
FI (1) FI882791A (no)
IL (1) IL86335A0 (no)
NO (1) NO882560L (no)
NZ (1) NZ224890A (no)
PT (1) PT87703A (no)
ZA (1) ZA884185B (no)

Families Citing this family (366)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045553A (en) * 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
US4941457A (en) * 1989-08-17 1990-07-17 Olympus Optical Co., Ltd. Endoscope using an optical guide twisted on the tip side to have the visual field direction and curvature axis coincide with each other
IT1243745B (it) * 1990-10-17 1994-06-21 Vectorpharma Int Composizioni terapeutiche transdermali contenenti farmaco e/o agente promotore dell'assorbimento cutaneo supportato su particelle microporose e microsfere polimeriche e loro preparazione.
US5326566A (en) * 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
US5990179A (en) * 1995-04-28 1999-11-23 Alza Corporation Composition and method of enhancing electrotransport agent delivery
US5985316A (en) * 1995-04-28 1999-11-16 Alza Corporation Composition and method of enhancing electrotransport agent delivery
US6420354B1 (en) 1998-06-08 2002-07-16 Advanced Medicine, Inc. Sodium channel drugs and uses
US6897305B2 (en) 1998-06-08 2005-05-24 Theravance, Inc. Calcium channel drugs and uses
US7101909B2 (en) * 1998-10-12 2006-09-05 Theravance, Inc. Calcium channel drugs and uses
US6479498B1 (en) 1999-06-04 2002-11-12 Theravance, Inc. Sodium channel drugs and uses
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
CA2398691A1 (en) 2000-02-18 2001-08-23 Cv Therapeutics, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
US20020012946A1 (en) * 2000-02-23 2002-01-31 Luiz Belardinelli Method of identifying partial agonists of the A2A receptor
US6638924B2 (en) 2000-08-30 2003-10-28 Pharmacyclics, Inc. Metallotexaphyrin derivatives
US7449454B2 (en) * 2000-08-30 2008-11-11 Pharmacyclics, Inc. Metallotexaphyrin derivatives
WO2002039953A2 (en) * 2000-11-17 2002-05-23 Pharmacyclics, Inc. Texaphyrin coordination compounds and uses thereof
IL156315A0 (en) 2000-12-07 2004-01-04 Cv Therapeutics Inc Abca-1 elevating compounds
US7157440B2 (en) * 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) * 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
CA2466477C (en) 2001-11-09 2012-10-02 Rao Kalla A2b adenosine receptor antagonists
CA2476683C (en) 2002-02-19 2011-11-01 Cv Therapeutics, Inc. Partial and full agonists of a1 adenosine receptors
US20030220344A1 (en) 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
NZ536678A (en) 2002-05-21 2007-01-26 Cv Therapeutics Inc Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
US7683037B2 (en) * 2002-07-29 2010-03-23 Gilead Palo Alto, Inc. Myocardial perfusion imaging method
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
NZ541306A (en) 2003-01-17 2008-07-31 Cv Therapeutics Inc Substituted piperazine and piperidine derivatives useful in the treatment of cardiovascular diseases
US7732467B2 (en) * 2003-05-15 2010-06-08 Alzheimer's Institute Of America, Inc. Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
US20070191815A1 (en) 2004-09-13 2007-08-16 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
CA2544678C (en) 2003-11-05 2013-12-31 Sunesis Pharmaceuticals, Inc. Modulators of cellular adhesion
US20060159627A1 (en) 2004-10-15 2006-07-20 Dewan Zeng Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
AU2005295437B2 (en) * 2004-10-20 2011-05-19 Gilead Palo Alto, Inc. Use of A2A adenosine receptor agonists
WO2006055672A2 (en) * 2004-11-16 2006-05-26 Limerick Neurosciences, Inc. Methods and compositions for treating pain
US20070087977A1 (en) * 2004-11-16 2007-04-19 Wendye Robbins Methods and compositions for treating pain
JP2006224318A (ja) * 2005-02-15 2006-08-31 Brother Ind Ltd インクジェット記録装置
US7670849B2 (en) * 2005-04-29 2010-03-02 Henkin Robert I Method for diagnosing insulin resistance from nasal secretions
US8506934B2 (en) * 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
PL2444079T3 (pl) 2005-05-17 2017-07-31 Sarcode Bioscience Inc. Kompozycje i sposoby leczenia chorób oczu
US7625881B2 (en) * 2005-06-16 2009-12-01 Gilead Palo Alto, Inc. Prodrugs of A2B adenosine receptor antagonists
EP1907395A1 (en) 2005-06-28 2008-04-09 Cv Therapeutics, Inc. Abca1 elevating compounds
US20070072838A1 (en) 2005-09-26 2007-03-29 Pharmacyclics, Inc. High-purity texaphyrin metal complexes
US20070078119A1 (en) * 2005-09-30 2007-04-05 Pharmacyclics, Inc. Storage system for texaphyrin pharmaceutical formulations
KR20080090491A (ko) * 2006-02-03 2008-10-08 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ2ａ-아데노신 수용체 효능제 및 이의 다형체의 제조 방법
US20070208040A1 (en) * 2006-03-02 2007-09-06 Elfatih Elzein A2a adenosine receptor antagonists
US20070219174A1 (en) * 2006-03-15 2007-09-20 Pharmacyclics, Inc. Methods of treating cancer using hypofractionated radiation and texaphyrins
US7702468B2 (en) 2006-05-03 2010-04-20 Population Diagnostics, Inc. Evaluating genetic disorders
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
EP2068850A1 (en) * 2006-06-22 2009-06-17 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
MX2008015765A (es) 2006-07-27 2009-03-26 Cv Therapeutics Inc Inhibidores de aldh-2 en el tratamiento de adiccion.
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
AU2007289037A1 (en) * 2006-09-01 2008-03-06 Gilead Sciences, Inc. Methods and compositions for increasing patient tolerability during myocardial imaging methods
JP2011502101A (ja) * 2006-09-29 2011-01-20 ギリアード・パロ・アルト・インコーポレイテッド 肺疾患の病歴を有する患者における心筋画像化法
US7893066B2 (en) * 2006-10-05 2011-02-22 Gilead Palo Alto, Inc. Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
CA2665476A1 (en) * 2006-10-05 2008-04-10 Cv Therapeutics, Inc. Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
MX2009007071A (es) * 2007-01-03 2009-10-13 Cv Therapeutics Inc Elaboracion de imagen de perfusion del miocardio.
WO2008095136A2 (en) 2007-01-31 2008-08-07 Henkin Robert I Methods for detection of biological substances
KR20110075044A (ko) 2007-04-02 2011-07-05 파킨슨즈 인스티튜트 처치 치료의 부작용을 감소시키기 위한 방법 및 조성물
CA2681560A1 (en) * 2007-04-09 2008-10-16 Cv Therapeutics, Inc. Pteridinone derivatives for use as stearoyl coa desaturase inhibitors
US20080255161A1 (en) * 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US20090105283A1 (en) * 2007-04-11 2009-04-23 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
GB2463833B (en) * 2007-06-26 2012-02-08 Parkinson S Inst Compositions that prevent or reverse alpha-synuclein fibrillation for use in the treatment of neurological disorders
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20100093810A1 (en) * 2007-10-05 2010-04-15 Alzheimer's Institute Of America, Inc. Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis
CA2701620C (en) * 2007-10-05 2014-12-09 Alzheimer's Institute Of America, Inc. Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer
CA2702984C (en) 2007-10-19 2017-04-11 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
MX2010007419A (es) 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
KR20100117105A (ko) * 2008-02-07 2010-11-02 질레드 팔로 알토 인코포레이티드 Ａｂｃａ-1 상승 화합물 및 이의 용도
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
EP2268637A1 (en) * 2008-04-04 2011-01-05 Gilead Sciences, Inc. Triazolopyridinone derivatives for use as stearoyl coa desaturase inhibitors
US20090258070A1 (en) * 2008-04-15 2009-10-15 John Burnier Topical LFA-1 antagonists for use in localized treatment of immune related disorders
US20090257957A1 (en) * 2008-04-15 2009-10-15 John Burnier Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
CN102065893A (zh) * 2008-04-15 2011-05-18 萨可德公司 Lfa-1拮抗剂向胃肠***的递送
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
US8580801B2 (en) * 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
MX2011003168A (es) * 2008-09-29 2011-05-19 Gilead Sciences Inc Combinaciones de un agente de control de cantidad y un antagonista del receptor a-2-alfa para utilizarse en metodos de tomografia computarizada de detectores multiples.
US8268887B2 (en) 2008-10-08 2012-09-18 Feng Xu Drug conjugates and methods of use thereof
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
WO2010045374A1 (en) * 2008-10-15 2010-04-22 Gilead Palo Alto, Inc. 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
WO2010056527A2 (en) 2008-10-30 2010-05-20 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
WO2010074807A1 (en) 2008-10-30 2010-07-01 Gilead Palo Alto, Inc. 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
WO2010056919A2 (en) * 2008-11-12 2010-05-20 Kyphia Pharmaceuticals, Inc. Eflornithine prodrugs, conjugates and salts, and methods of use thereof
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
EP2429526A1 (en) * 2009-05-14 2012-03-21 Gilead Sciences, Inc. Ranolazine for the treatment of cns disorders
US20110038852A1 (en) * 2009-06-10 2011-02-17 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
HUE034911T2 (hu) 2009-07-27 2018-03-28 Gilead Sciences Inc Fúzionált heterociklusos vegyületek mint ioncsatorna modulátorok
WO2011019752A2 (en) 2009-08-14 2011-02-17 Gilead Palo Alto, Inc. A1 adenosine receptor agonist polymorphs
MX2012002066A (es) 2009-08-17 2012-03-29 Intellikine Inc Compuestos heterociclicos y usos de los mismos.
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
PT2545052E (pt) 2010-03-11 2015-02-18 Gilead Connecticut Inc Inibidores da syk à base de imidazopiridinas
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
WO2012003220A1 (en) 2010-06-30 2012-01-05 Gilead Sciences, Inc. Use of a2b adenosine receptor antagonists for treating pulmonary hypertension
ES2529119T3 (es) 2010-07-02 2015-02-17 Gilead Sciences, Inc. Compuestos heterocíclicos condensados como moduladores de canales iónicos
EA023040B1 (ru) 2010-07-02 2016-04-29 Джилид Сайэнс, Инк. Ингибиторы киназ, регулирующих апоптозный сигнал
WO2012018387A2 (en) 2010-08-02 2012-02-09 Population Diagnotics, Inc. Compositions and methods for discovery of causative mutations in genetic disorders
CA2817577A1 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8236288B2 (en) 2011-01-07 2012-08-07 Skinmedica, Inc. Melanin modification compositions and methods of use
TWI546305B (zh) 2011-01-10 2016-08-21 英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
MX342287B (es) 2011-03-08 2016-09-23 3-V Biosciences Inc Moduladores heterociclicos de sintesis lipidica.
AR085942A1 (es) 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
JP5934787B2 (ja) 2011-05-10 2016-06-15 ギリアード サイエンシーズ， インコーポレイテッド イオンチャネルモジュレーターとしての縮合複素環式化合物
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
NO3175985T3 (no) 2011-07-01 2018-04-28
AU2012284091B2 (en) 2011-07-19 2015-11-12 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
EP2751093A1 (en) 2011-08-29 2014-07-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AR087700A1 (es) 2011-08-30 2014-04-09 Gilead Sciences Inc Inhibidores de aldh-2 en el tratamiento de adicciones
WO2013043925A1 (en) 2011-09-21 2013-03-28 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
US10221454B2 (en) 2011-10-10 2019-03-05 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
WO2013067451A2 (en) 2011-11-04 2013-05-10 Population Diagnostics Inc. Methods and compositions for diagnosing, prognosing, and treating neurological conditions
WO2013120018A1 (en) 2012-02-09 2013-08-15 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
US9452215B2 (en) 2012-02-22 2016-09-27 The Regents Of The University Of Colorado Bourvadin derivatives and therapeutic uses thereof
EP3345624A1 (en) 2012-02-22 2018-07-11 The Regents Of The University Of Colorado Bouvardin derivatives and therapeutic uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8969588B2 (en) 2012-06-05 2015-03-03 Gilead Pharmasset Llc Solid forms of an antiviral compound
US9321749B1 (en) 2012-07-25 2016-04-26 Globavir Biosciences, Inc. Heterocyclic compounds and uses thereof
JP6607780B2 (ja) 2012-07-25 2019-11-20 サルコード・バイオサイエンス・インコーポレイテッド Ｌｆａ−１阻害剤およびその多形
US8841340B2 (en) 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
DK2895621T3 (da) 2012-09-14 2020-11-30 Population Bio Inc Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande
CA2922005A1 (en) 2012-09-27 2014-04-03 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
US20140120060A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
CN105102000B (zh) 2012-11-01 2021-10-22 无限药品公司 使用pi3激酶亚型调节剂的癌症疗法
ES2677919T3 (es) 2012-12-21 2018-08-07 Gilead Calistoga Llc Aminoalquil-quinazolonas sustituidas con pirimidina como inhibidores de la fosfatidilinositol 3-quinasa
UY35212A (es) 2012-12-21 2014-06-30 Gilead Sciences Inc Inhibidores de la quinasa que regula la señal de la apoptosis
NZ708870A (en) 2012-12-21 2016-09-30 Gilead Calistoga Llc Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
CN104884064A (zh) 2012-12-24 2015-09-02 纽洛佳斯特拉斯公司 用于治疗胃肠道病症的方法
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
EP2970194A1 (en) 2013-03-15 2016-01-20 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
TWI530499B (zh) * 2013-03-28 2016-04-21 吉李德科學股份有限公司 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
EP3003309B1 (en) 2013-05-30 2020-09-09 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
AR096621A1 (es) 2013-06-14 2016-01-20 Gilead Sciences Inc Inhibidores de isómeros de la fosfatidilinositol 3-quinasa (pi3k)
ES2656192T3 (es) 2013-07-31 2018-02-26 Gilead Sciences, Inc. Inhibidores de SKY
HUE036600T2 (hu) 2013-10-03 2018-07-30 Kura Oncology Inc ERK inhibitorok és alkalmazási eljárások
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG10201902074UA (en) 2013-10-04 2019-04-29 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
WO2015061204A1 (en) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6262363B2 (ja) 2013-11-26 2018-01-17 ギリアード サイエンシーズ， インコーポレイテッド ブロモドメイン阻害剤としてのキノリン誘導体
DK3076976T3 (da) 2013-12-04 2020-12-07 Kronos Bio Inc Fremgangsmåder til behandling af cancer
US10328080B2 (en) 2013-12-05 2019-06-25 Acerta Pharma, B.V. Therapeutic combination of PI3K inhibitor and a BTK inhibitor
PT3083608T (pt) 2013-12-19 2018-11-09 Gilead Sciences Inc Compostos heterocíclicos fundidos como moduladores de canal iónico
WO2015100144A1 (en) 2013-12-23 2015-07-02 Gilead Sciences, Inc. Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide
TWI662037B (zh) 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
WO2015110923A2 (en) 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
TW201613908A (en) 2014-02-13 2016-04-16 Gilead Sciences Inc Solid forms of an ion channel modulator
CN106233141B (zh) 2014-02-18 2018-08-21 罗伯特·I·汉金 用于诊断和治疗味觉或嗅觉的损失和/或失真的方法和组合物
US9775844B2 (en) 2014-03-19 2017-10-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015185998A2 (en) 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
WO2015181633A2 (en) 2014-04-11 2015-12-03 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
WO2015175845A1 (en) 2014-05-15 2015-11-19 Peloton Therapeutics, Inc. Benzimidazole derivatives and uses thereof
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
CN106459005A (zh) 2014-06-13 2017-02-22 吉利德科学公司 磷脂酰肌醇3‑激酶抑制剂
EA201692265A1 (ru) 2014-06-13 2017-05-31 Джилид Сайэнс, Инк. Ингибиторы фосфатидилинозитол-3-киназы
CN106559991B (zh) 2014-06-19 2019-09-20 阿里亚德医药股份有限公司 用于激酶抑制的杂芳基化合物
US9844554B2 (en) 2014-06-24 2017-12-19 Neurogastrx, Inc. Prodrugs of metopimazine
MA40075A (fr) 2014-07-14 2016-01-21 Gilead Sciences Inc Combinaisons pour traiter des cancers
US10759836B2 (en) 2014-07-18 2020-09-01 University Of Washington Cancer vaccine compositions and methods of use thereof
WO2016024227A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
TW201609099A (zh) 2014-08-11 2016-03-16 艾森塔製藥公司 使用布魯頓（Ｂｒｕｔｏｎ）氏酪胺酸激酶（ＢＴＫ）抑制劑以治療慢性淋巴球性白血病和小淋巴球性白血病之方法
CA2996445A1 (en) 2014-09-05 2016-03-10 Eli Hatchwell Methods and compositions for inhibiting and treating neurological conditions
ES2727376T3 (es) 2014-09-26 2019-10-15 Gilead Sciences Inc Derivados de aminotriazina útiles como compuestos inhibidores de quinasa de unión TANK
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2016055982A1 (en) 2014-10-10 2016-04-14 Acerta Pharma B.V. Quinoline and quinazoline compounds
ES2813726T3 (es) 2014-10-21 2021-03-24 Ariad Pharma Inc Formas cristalinas de 5-cloro-N4-[-2-(dimetilfosforilo)fenilo]-N2-{2-metoxi-4-[4-(4-metilpiperazina-1-ilo)piperidina-1- ilo]pirimidina-2,4-diamina
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
EP4385575A2 (en) 2015-01-28 2024-06-19 Duke University Composition comprising methylphenidate and ondansetron for use in substance-related disorders
US10213586B2 (en) 2015-01-28 2019-02-26 Chrono Therapeutics Inc. Drug delivery methods and systems
WO2016144826A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
WO2016145032A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
US10189822B2 (en) 2015-03-19 2019-01-29 3-V Biosciences, Inc. Heterocyclic modulators of lipid synthesis
IL293770B2 (en) 2015-07-06 2023-07-01 Gilead Sciences Inc Modulators of cot and methods of using them
EP3319938B1 (en) 2015-07-10 2022-04-06 University of Maryland, Baltimore Small molecule inhibitors of the mcl-1 oncoprotein and uses thereof
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
MA44909A (fr) 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
US20190022092A1 (en) 2015-09-15 2019-01-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
JP6908805B2 (ja) 2015-11-11 2021-07-28 アンビエント フォトニクス， インコーポレイテッド Ｃｎｓおよび他の障害の処置のためのベンゾフラン誘導体
MX2018007421A (es) 2015-12-17 2018-08-15 Gilead Sciences Inc Compuestos inhibidores de quinasa de union a tank.
US20190008869A1 (en) 2016-01-13 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of an Antifolate and a BTK Inhibitor
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
JP2019510752A (ja) 2016-03-04 2019-04-18 ギリアード サイエンシーズ， インコーポレイテッド オートタキシン阻害剤の組成物及び合剤
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017218802A1 (en) 2016-06-15 2017-12-21 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
US20190151324A1 (en) 2016-06-23 2019-05-23 University Of Maryland, Baltimore NON-CATALYTIC SUBSTRATE-SELECTIVE P38alpha-SPECIFIC MAPK INHIBITORS WITH ENDOTHELIAL-STABILIZING AND ANTI-INFLAMMATORY ACTIVITY, AND METHODS OF USE THEREOF
ES2800339T3 (es) 2016-06-30 2020-12-29 Gilead Sciences Inc 4,6-diaminoquinazolinas como moduladores de cuna y métodos de uso de los mismos
WO2018053190A1 (en) 2016-09-14 2018-03-22 Gilead Sciences, Inc. Syk inhibitors
TW201822764A (zh) 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑
WO2018057808A1 (en) 2016-09-23 2018-03-29 Gilead Sciences, Inc. Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018055577A1 (en) 2016-09-23 2018-03-29 Synthena Ag Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018075601A1 (en) 2016-10-18 2018-04-26 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018085833A2 (en) 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyl transferase 5 (prmt5)
WO2018085818A1 (en) 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018098491A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
BR112019010880A2 (pt) 2016-11-28 2019-10-01 Praxis Prec Medicines Inc compostos e seus métodos de uso
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
US11285306B2 (en) 2017-01-06 2022-03-29 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
ES2914123T3 (es) 2017-01-09 2022-06-07 Shuttle Pharmaceuticals Inc Inhibidores selectivos de la histona desacetilasa para el tratamiento de una enfermedad humana
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
WO2018148745A1 (en) 2017-02-13 2018-08-16 Praxis Precision Medicines , Inc. Compounds and their methods of use
WO2018152548A1 (en) 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018152501A1 (en) 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018160824A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018160855A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018175324A1 (en) 2017-03-20 2018-09-27 The Broad Institute, Inc. Compounds and methods for regulating insulin secretion
US11731966B2 (en) 2017-04-04 2023-08-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018195471A1 (en) 2017-04-21 2018-10-25 Gilead Sciences, Inc. Syk inhibitors in combination with hypomethylating agents
EP3621945A4 (en) 2017-05-09 2021-03-03 Ambient Photonics, Inc. STYLE DERIVATIVES FOR THE TREATMENT OF THE CNS AND OTHER DISEASES
EP4403171A2 (en) 2017-06-19 2024-07-24 University of Maryland, Baltimore Microtubule polymerization inhibitor prodrugs and methods of using the same
KR20200036922A (ko) 2017-08-09 2020-04-07 프렐루드 테라퓨틱스, 인코포레이티드 단백질 아르기닌 메틸트랜스퍼라제 5 (prmt5)의 선택적 억제제
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
EP3672970A1 (en) 2017-08-22 2020-07-01 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
WO2019055490A1 (en) 2017-09-14 2019-03-21 The Board Of Trustees Of The Leland Stanford Junior University PACKAGING OF IRRADIED FABRIC FOR FAT GREETING RETENTION
CN111655666B (zh) 2017-09-28 2023-11-07 麦迪康制药公司 抗炎、抗癌和抗血管生成化合物，药物组合物及其制备和使用方法
JOP20180092A1 (ar) 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
US11524962B2 (en) 2017-10-26 2022-12-13 Prelude Therapeutics, Incorporated Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5)
US20200340060A1 (en) 2017-11-13 2020-10-29 Gilead Sciences, Inc. Compositions and methods for identifying and treating liver diseases and monitoring treatment outcomes
CN112004537A (zh) 2018-01-09 2020-11-27 穿梭药业公司 用于治疗人疾病的选择性组蛋白去乙酰化酶抑制剂
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
US10696657B2 (en) 2018-02-16 2020-06-30 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds
CN114195672A (zh) 2018-03-02 2022-03-18 俄勒冈健康科学大学 小分子核受体调节剂的酰胺前药
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
DK3765461T3 (da) 2018-03-14 2023-11-20 Prelude Therapeutics Inc Selektive protein argininmethyltransferase 5 (prmt5)-hæmmere
EP3778589B1 (en) 2018-04-09 2022-05-11 Weishang (Shanghai) Bio-Pharmaceutical Co., Ltd. 5-substituted difluoropiperidine compound capable of passing through blood-brain barrier
EP4227293A3 (en) 2018-05-14 2023-10-04 Xgene Pharmaceutical Inc Crystalline forms of 1-(acyloxy)-alkyl carbamate drug conjugates of naproxen and pregabalin
EP3801732A4 (en) 2018-05-29 2022-04-27 Morningside Venture Investments Limited DRUG DELIVERY METHODS AND SYSTEMS
CN112423760A (zh) 2018-05-30 2021-02-26 普拉克西斯精密药物股份有限公司 离子通道调节剂
JP7049519B2 (ja) 2018-07-06 2022-04-06 ギリアード サイエンシーズ， インコーポレイテッド 治療用複素環式化合物
EP3817818A1 (en) 2018-07-06 2021-05-12 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
WO2020018459A1 (en) 2018-07-16 2020-01-23 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
TWI766172B (zh) 2018-07-30 2022-06-01 美商基利科學股份有限公司 抗hiv化合物
CA3108807A1 (en) 2018-08-08 2020-02-13 Pml Screening, Llc Methods for assessing the risk of developing progressive multifocal leukoencephalopathy caused by john cunningham virus by genetic testing
CA3110877A1 (en) 2018-08-27 2020-03-05 Spinogenix, Inc. Fascin binding compounds for spinogenesis
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
WO2020072656A1 (en) 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
CA3116347A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
FI3873903T3 (fi) 2018-10-31 2024-03-26 Gilead Sciences Inc Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina
EP3877390A1 (en) 2018-11-09 2021-09-15 Prelude Therapeutics, Incorporated Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
MX2021005887A (es) 2018-11-19 2021-09-14 Global Blood Therapeutics Inc Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular hemoglobina.
NZ777458A (en) 2018-12-07 2024-03-22 Univ Maryland Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors
AU2019397067A1 (en) 2018-12-12 2021-07-22 Autobahn Therapeutics, Inc. Novel thyromimetics
EP3894416B1 (en) 2018-12-13 2022-11-09 Global Blood Therapeutics, Inc. Ferroportin inhibitors and methods of use
WO2020123994A1 (en) 2018-12-14 2020-06-18 Prelude Therapeutics, Incorporated 2-((5-(phenyl)-pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-3-(phenyl)propanoic acid derivatives and related compounds as mcl-1 enzyme inhibitors for treating cancer
EP3920906A4 (en) 2019-02-06 2023-07-12 Oregon Health & Science University COMPOUNDS RELATED TO BISPHOSPHONATES
KR20210129051A (ko) 2019-02-13 2021-10-27 프렐루드 테라퓨틱스, 인코포레이티드 단백질 아르기닌 메틸트랜스퍼라제 5(prmt5)의 선택적 억제제
MX2021010131A (es) 2019-02-22 2021-11-18 Kronos Bio Inc Formas sólidas de pirazinas condensadas a manera de inhibidores de syk.
WO2020176424A1 (en) 2019-02-25 2020-09-03 Chdi Foundation, Inc. Compounds for targeting mutant huntingtin protein and uses thereof
WO2020176510A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
WO2020176505A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
CA3130371A1 (en) 2019-03-01 2020-09-10 Autobahn Therapeutics, Inc. Novel thyromimetics
TW202104210A (zh) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
MX2021013421A (es) 2019-05-03 2022-02-11 Praxis Prec Medicines Inc Inhibidores de kcnt1 y metodos de uso.
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
TWI770527B (zh) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
AU2020311942A1 (en) 2019-07-11 2022-02-24 Praxis Precision Medicines, Inc. Formulations of T-type calcium channel modulators and methods of use thereof
AU2020349553A1 (en) 2019-09-18 2022-04-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
US20220315579A1 (en) 2019-09-26 2022-10-06 Exelixis, Inc. Pyridone compounds and methods of use
TW202133846A (zh) 2019-11-26 2021-09-16 美商基利科學股份有限公司 預防hiv之蛋白殼抑制劑
CA3163091A1 (en) 2019-11-27 2021-06-03 Praxis Precision Medicines, Inc. Formulations of ion channel modulators and methods of preparation and use of ion channel modulators
WO2021155253A1 (en) 2020-01-31 2021-08-05 Atomwise Inc. Anat inhibitors and methods of use thereof
US11697652B2 (en) 2020-02-24 2023-07-11 Gilead Sciences, Inc. Tetracyclic compounds and uses thereof
AU2021226747A1 (en) 2020-02-24 2022-09-01 Exelixis, Inc. Compounds and methods of use
JP2023520650A (ja) 2020-03-30 2023-05-18 ギリアード サイエンシーズ， インコーポレイテッド （Ｓ）－６－（（（１－（ビシクロ［１．１．１］ペンタン－１－イル）－１Ｈ－１，２，３－トリアゾール－４－イル）２－メチル－１－オキソ－１，２－ジヒドロイソキノリン－５－イル）メチル）））アミノ）８－クロロ－（ネオペンチルアミノ）キノリン－３－カルボニトリルＣｏｔ阻害剤化合物の固体形態
CA3176429A1 (en) 2020-03-31 2021-10-07 Global Blood Therapeutics, Inc. Modulators of hemoglobin
US20230159538A1 (en) 2020-04-01 2023-05-25 Global Blood Therapeutics, Inc. Pyrrolidine-pyrazoles as pyruvate kinase activators
JP7446475B2 (ja) 2020-04-02 2024-03-08 ギリアード サイエンシーズ， インコーポレイテッド Ｃｏｔ阻害剤化合物を調製するためのプロセス
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
WO2021211922A1 (en) 2020-04-16 2021-10-21 Prelude Therapeutics, Incorporated Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
US20230226074A1 (en) 2020-04-28 2023-07-20 Global Blood Therapeutics, Inc. Methods of use for pyrimidines as ferroportin inhibitors
WO2021222359A1 (en) 2020-04-28 2021-11-04 Global Blood Therapeutics, Inc. Thieno pyrimidines as ferroportin inhibitors
CR20220556A (es) 2020-04-28 2022-12-15 Global Blood Therapeutics Inc Pirimidinas cicloalquiladas como inhibidores de la ferroportina
US20230357275A1 (en) 2020-05-13 2023-11-09 Prelude Therapeutics, Incorporated Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
IL298933A (en) 2020-06-09 2023-02-01 Prelude Therapeutics Inc BRM-targeted compounds and related methods of use
CN115996925A (zh) 2020-06-25 2023-04-21 吉利德科学公司 用于治疗hiv的衣壳抑制剂
CA3190593A1 (en) 2020-08-03 2022-02-10 Global Blood Therapeutics, Inc. Urea derivatives as pyruvate kinase activators
EP4192952A1 (en) 2020-08-10 2023-06-14 Novartis AG Treatments for retinal degenerative diseases
EP4214213A1 (en) 2020-09-21 2023-07-26 Prelude Therapeutics, Incorporated Cdk inhibitors and their use as pharmaceuticals
TW202222798A (zh) 2020-09-30 2022-06-16 美商基利科學股份有限公司 橋接三環胺甲醯基吡啶酮化合物及其用途
WO2022069701A1 (en) 2020-10-01 2022-04-07 Nogra Pharma Limited Methods of treating pulmonary fibrosis
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
EP4240743A1 (en) 2020-11-06 2023-09-13 Prelude Therapeutics, Incorporated Brm targeting compounds and associated methods of use
IL303779A (en) 2020-12-18 2023-08-01 Prelude Therapeutics Inc CDK inhibitors and their use as drugs
WO2022140326A1 (en) 2020-12-22 2022-06-30 Gilead Sciences, Inc. Substituted indole compounds
WO2022140325A1 (en) 2020-12-22 2022-06-30 Gilead Sciences, Inc. 6-substituted indole compounds
CA3202944A1 (en) 2020-12-23 2022-06-30 David BAUMAN Pyrazolothiazole carboxamides and their uses as pdgfr inhibitors
PE20240687A1 (es) 2020-12-30 2024-04-10 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas
CR20230315A (es) 2021-01-19 2023-09-01 Gilead Sciences Inc Compuestos de piridotriazina sustituidos y usos de estos
WO2022170200A1 (en) 2021-02-08 2022-08-11 Global Blood Therapeutics, Inc. 1-(2-sulfonyl-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4h)-yl]-ethanone derivatives as pyruvate kinase (pkr) and pkm2 activators for the treatment of sickle cell disease
EP4291562A1 (en) 2021-02-09 2023-12-20 Gilead Sciences, Inc. Thienopyrrole compounds
US20240158393A1 (en) 2021-02-19 2024-05-16 Exelixis, Inc. Pyridone compounds and methods of use
US11661431B2 (en) 2021-04-16 2023-05-30 Gilead Sciences, Inc. Thienopyrrole compounds
EP4337659A1 (en) 2021-05-14 2024-03-20 Global Blood Therapeutics, Inc. Solid forms of a modulator of hemoglobin
TW202304435A (zh) 2021-06-04 2023-02-01 美商基利科學股份有限公司 治療ｎａｓｈ之方法
WO2022266370A1 (en) 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan for treating idiopathic pulmonary fibrosis
TW202311256A (zh) 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑
WO2023279041A1 (en) 2021-06-30 2023-01-05 Tyra Biosciences, Inc. Indazole compounds
TW202317533A (zh) 2021-07-02 2023-05-01 美商雅斯治療公司 奧沙奈坦(osanetant)之固體形式
WO2023287787A1 (en) 2021-07-13 2023-01-19 Prelude Therapeutics, Incorporated Brm targeting compounds and associated methods of use
TW202313053A (zh) 2021-07-30 2023-04-01 瑞士商艾克泰聯製藥有限公司 吡唑并嘧啶及其作為ｐｄｇｆｒ抑制劑之用途
WO2023034530A1 (en) 2021-09-02 2023-03-09 Teon Therapeutics, Inc. Methods of improving growth and function of immune cells
WO2023039464A1 (en) 2021-09-10 2023-03-16 Gilead Sciences, Inc. Thienopyrrole compounds
WO2023056441A1 (en) 2021-09-30 2023-04-06 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals
WO2023060134A1 (en) 2021-10-06 2023-04-13 Global Blood Therapeutics, Inc. Lactam pyrrolidine-pyrazoles as pyruvate kinase activators
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
WO2023081730A1 (en) 2021-11-03 2023-05-11 Teon Therapeutics, Inc. 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
WO2023097233A1 (en) 2021-11-23 2023-06-01 Genentech, Inc. Spirocyclic cyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
WO2023097230A1 (en) 2021-11-23 2023-06-01 Genentech, Inc. Spirocyclic bicyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
WO2023097234A1 (en) 2021-11-23 2023-06-01 Genentech, Inc. Spirocyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
CA3237155A1 (en) 2021-12-03 2023-06-08 Zhimin Du Therapeutic compounds for hiv virus infection
CA3238270A1 (en) 2021-12-03 2023-06-08 Gediminas J. Brizgys Therapeutic compounds for hiv virus infection
US11787825B2 (en) 2021-12-03 2023-10-17 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
CA3241881A1 (en) 2021-12-10 2023-06-15 Global Blood Therapeutics, Inc. Methods of administering a modulator of hemoglobin
WO2023141571A1 (en) 2022-01-21 2023-07-27 Prelude Therapeutics, Incorporated Cdk inhibitors and their use as pharmaceuticals
WO2023147312A1 (en) 2022-01-25 2023-08-03 Evvia Therapeutics, Inc. Ampk agonists and methods of use thereof
WO2023147135A1 (en) 2022-01-31 2023-08-03 Acer Therapeutics, Inc. Nk receptor antagonists for treatment of prostate cancer
WO2023147134A2 (en) 2022-01-31 2023-08-03 Acer Therapeutics, Inc. Methods for treating patients having low estrogen with nk3 antagonists
WO2023150612A1 (en) 2022-02-03 2023-08-10 Prelude Therapeutics, Incorporated Cdk inhibitors and their use as pharmaceuticals
US20240018136A1 (en) 2022-03-09 2024-01-18 Prelude Therapeutics, Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
WO2023178547A1 (en) 2022-03-23 2023-09-28 Prelude Therapeutics, Incorporated Polymorphic compounds and uses thereof
US20240124422A1 (en) 2022-03-29 2024-04-18 Prelude Therapeutics Incorporated Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
WO2023192506A1 (en) 2022-03-31 2023-10-05 Rarified Biosciences, Inc. Malt1 modulators and uses thereof
TW202400172A (zh) 2022-04-06 2024-01-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2023215220A1 (en) 2022-05-02 2023-11-09 Esperion Therapeutics, Inc. Macrocyclic inhibitors of atp citrate lyase
WO2023220577A1 (en) 2022-05-10 2023-11-16 Prelude Therapeutics, Incorporated 6,6a,7,8,9,10-hexahydro-5h-pyrazino[1',2':4,5]pyrazino[2,3-c]pyridazine derivatives as smarca4 protein degraders for the treatment of cancer
US20240101529A1 (en) 2022-05-20 2024-03-28 Gilead Sciences, Inc. Antiviral indolinyl compounds and uses thereof
US12018009B2 (en) 2022-06-14 2024-06-25 Amygdala Neurosciences, Inc. ALDH-2 inhibitor compounds and methods of use
WO2023244563A1 (en) 2022-06-14 2023-12-21 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use
WO2023245150A1 (en) 2022-06-16 2023-12-21 Prelude Therapeutics Incorporated Kat6 targeting compounds with ubiquitin ligase binding moiety
WO2023247596A1 (en) 2022-06-22 2023-12-28 Actelion Pharmaceuticals Ltd Pyrazolothiazole carboxamides and their uses as pdgfr inhibitors
WO2023247593A1 (en) 2022-06-22 2023-12-28 Actelion Pharmaceuticals Ltd Pyrrolopyridine carboxamides and their uses as pdgfr inhibitors
WO2023247590A1 (en) 2022-06-22 2023-12-28 Actelion Pharmaceuticals Ltd Triazolopyridine and benzoisoxazole carboxamides and their uses as pdgfr inhibitors
WO2023247595A1 (en) 2022-06-22 2023-12-28 Actelion Pharmaceuticals Ltd Pyrazolopyrazine carboxamides and their uses as pdgfr inhibitors
WO2024006897A1 (en) 2022-06-29 2024-01-04 Tyra Biosciences, Inc. Indazole compounds
TW202408493A (zh) 2022-06-29 2024-03-01 美商泰拉生物科學公司 多晶形化合物及其用途
WO2024015827A1 (en) 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. Solid forms of a triazine derivative as cbl-b modulator
WO2024015372A1 (en) 2022-07-14 2024-01-18 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
WO2024013724A1 (en) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd Antibody-drug conjugates
WO2024015416A1 (en) 2022-07-15 2024-01-18 Celloram Inc. Celastrol derivatives
WO2024047394A1 (en) 2022-08-31 2024-03-07 Otsuka Pharmaceutical Co., Ltd. Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine
US20240150340A1 (en) 2022-10-06 2024-05-09 Prelude Therapeutics Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
WO2024089668A1 (en) 2022-10-28 2024-05-02 Basecamp Bio Inc. Somatostatin receptor 2 agonists and uses thereof
WO2024104968A1 (en) 2022-11-14 2024-05-23 Actelion Pharmaceuticals Ltd Pyrazolopyrrolopyridazines and their uses as pdgfr inhibitors
US20240190886A1 (en) 2022-11-15 2024-06-13 Prelude Therapeutics Incorporated BRM Targeting Compounds and Associated Methods of Use
WO2024138112A1 (en) 2022-12-22 2024-06-27 Tyra Biosciences, Inc. Indazole compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284634A (en) * 1975-07-02 1981-08-18 Fujisawa Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives, and pharmaceutical method of the same
US4338322A (en) * 1975-07-02 1982-07-06 Fujisawa Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same
JPS58177916A (ja) * 1982-04-13 1983-10-18 Kowa Co 外用剤
JPS5923673A (ja) * 1982-07-30 1984-02-07 Toshiba Corp 映像ハ−フト−ン回路
JPS5939827A (ja) * 1982-08-27 1984-03-05 Nitto Electric Ind Co Ltd 医療用外用部材
DE3307422A1 (de) * 1983-03-03 1984-09-06 Bayer Ag, 5090 Leverkusen Fluessigzubereitungen von dihydropyridinen, ein verfahren zu ihrer herstellung, sowie ihre verwendung bei der bekaempfung von erkrankungen
JPS59175415A (ja) * 1983-03-25 1984-10-04 Nitto Electric Ind Co Ltd 医薬製剤
JPS6016917A (ja) * 1983-07-08 1985-01-28 Yamanouchi Pharmaceut Co Ltd 塩酸ニカルジピンまたはニフエジピンの軟膏剤
JPS60174716A (ja) * 1984-02-21 1985-09-09 Yamanouchi Pharmaceut Co Ltd パツチ剤
DE3424553A1 (de) * 1984-07-04 1986-01-09 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen mit dihydropyridinen und verfahren zu ihrer herstellung
JPS6118717A (ja) * 1984-07-05 1986-01-27 Nichiban Co Ltd ニフエジピン含有貼布剤
DE3447170A1 (de) * 1984-12-22 1986-07-03 Bayer Ag, 5090 Leverkusen Mischung unterschiedlicher dihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln

Also Published As

Publication number Publication date
JPS6413023A (en) 1989-01-17
NO882560L (no) 1988-12-13
NZ224890A (en) 1992-06-25
NO882560D0 (no) 1988-06-10
AU1760988A (en) 1988-12-15
EP0321636A2 (en) 1989-06-28
FI882791A0 (fi) 1988-06-10
IL86335A0 (en) 1988-11-15
PT87703A (pt) 1989-05-31
DK316988D0 (da) 1988-06-10
AU614523B2 (en) 1991-09-05
CA1305419C (en) 1992-07-21
ZA884185B (en) 1989-03-29
EP0321636A3 (en) 1989-09-27
KR890000091A (ko) 1989-03-11
FI882791A (fi) 1988-12-13
US5001139A (en) 1991-03-19

Similar Documents

Publication Publication Date Title
DK316988A (da) Transdermalt farmaceutisk praeparat og dets anvendelse
DK589086A (da) Farmaceutisk sustained release praeparat indeholdende dextromethorphansamt dets fremstilling og anvendelse
DK551187A (da) Terapeutisk praeparat og dettes fremstilling
DK609689A (da) Folielaminat og dets anvendelse
DK349088A (da) Haerdelige blandinger og deres anvendelse
DK285388A (da) Peptid og dets anvendelse
DK84588D0 (da) Phenylguanidin- og tetrahydropyrimidinholdigt anthelmikum, dets fremstilling og anvendelse
DK287188A (da) Cephalosporinforbindelser og farmaceutisk praeparat deraf
DK381886A (da) Medicinsk praeparat og fremgangsmaade til dets fremstilling
DK293888D0 (da) Fenolderivater og deres fremstilling og anvendelse
DK650089D0 (da) Furanalkylketoner og farmaceutiske praeparater deraf
DK420986A (da) Dihydropyridin-2-hydroxyaminer, fremgangsmaade til deres fremstilling og deres anvendelse i laege-midler
DK590987D0 (da) Peptid og farmaceutisk praeparat indeholdende et saadant peptid
DK424987A (da) Farmaceutisk praeparat til indgivelse gennem huden og fremgangsmaade til dets fremstilling
DK285288A (da) Peptid og dets anvendelse
NO175630C (no) Legemiddelpakning og kombinasjonspakning
DK501989D0 (da) Mikrobiocidt praeparat og dettes fremstilling
DK701588D0 (da) N-hydroxy-5-phenyl-2-furancarboximidamider og anvendelse heraf til fremstilling af farmceutiske praeparater
NO870299D0 (no) Liposom/antrakinon-legemiddelpreparat og fremgangsmaate for dets fremstilling.
DK66087A (da) Karbocykliske purinnukleosider og anvendelse og fremstilling deraf
DK588887D0 (da) Farmaceutisk praeparat og fremgangsmaade til dets fremstilling
NO863783D0 (no) Amidinoureaprosess og farmasoeytisk preparat.
DK363786D0 (da) Hydroquinoliner og anvendelse deraf
BR1100961A (pt) Composto e composição farmacêutica
DK595287D0 (da) Azabicykliske forbindelser, deres fremstilling og anvendelse

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment